Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

PhAse 1/2 StuDy of Modern ImmunotherApy in BCG-Unresponsive, BCG-RelaPsing, and High-Risk BCG-Naive Non-muscle Invasive UroThelial Carcinoma of the BLADDER

NCT03317158 is registered in ClinicalTrials.gov with Noah Hahn, M.D. as lead sponsor.

NCT NCT03317158
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03317158 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
PhAse 1/2 StuDy of Modern ImmunotherApy in BCG-Unresponsive, BCG-RelaPsing, and High-Risk BCG-Naive Non-muscle Invasive UroThelial Carcinoma of the BLADDER
Lead sponsor
Noah Hahn, M.D.
Phase
Phase 1/2
Overall status
Active, not recruiting
Start date
November 21, 2017
Completion date
December 31, 2029
Enrollment
186 (estimated)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

bladder cancer, urothelial carcinoma